News

Japan-based Eisai has reported completion of construction of a new manufacturing and process research center in India. Eisai Knowledge Centre is situated in the special economic zone (SEZ)

The US Patent and Trademark Office (USPTO) has allowed patent application US 11/627,863 to MDRNA. It covers methods for the delivery of a broad array of compounds with

Synta Pharmaceuticals (Synta) has initiated a Phase 2 clinical study of STA-9090 in non-small cell lung cancer (NSCLC). STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a

Clinuvel has announced that its photoprotective drug Afamelanotide has been granted an orphan drug designation (ODD) by the FDA for the management of solar urticaria (SU). This is

Virtual Radiologic has completed the deployment of vRad PACS, its proprietary picture communications and archiving system for radiologic case processing. Replacing previously used commercial software, vRad PACS is

Roche has licensed its P2X31 receptor program aimed at developing treatments for chronic pain to Afferent Pharmaceuticals (Afferent). In conjunction with the announcement, Afferent has successfully closed a

Auxilium has reported top-line efficacy and safety results for the phase IIb clinical trial for Xiaflex (collagenase clostridium histolyticum) in the treatment of peyronie’s disease. The phase IIb

ThromboGenics has completed the enrollment of the second Phase III trial evaluating Microplasmin for the non-surgical treatment of eye disease. The trial TG-MV-007, which recruited patients both in

Naurex has initiated a Phase I clinical trial of its GLYX-13 and has successfully dosed the first subjects in the study. GLYX-13, a glycine site functional partial agonist